Bharat Parenterals Subsidiary Undergoes U.S. FDA Inspection; Five Observations Issued
Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences Private Limited, recently underwent a surprise and unannounced inspection by the United States Food and Drug Administration (U.S. FDA) at its finished dosage manufacturing facility in Vadodara, Gujarat.The inspection focused on the General Injectables Block and took place across multiple dates: April 13, 2026 to April 17, 2026, and April 20, 2026.Following the conclusion of the review, the U.S. FDA issued five (5) observations, classifying them under a Voluntary Action Indicated (VAI) category. The company's subsidiary has committed to submitting its formal response within the prescribed...